Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04585035 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate D-1553 in Subjects With Solid Tumors

A Phase 1 study of Solid Tumor, Adult and NSCLC, sponsored by InventisBio Co..

Active
Registry status
Phase 1
Development phase
180
Enrollment target
20
Study locations

NCT04585035 is a Phase 1 study of Solid Tumor, Adult and NSCLC that is active but no longer recruiting, run by InventisBio Co.. The registered enrollment target is 180 participants, roughly in line with the 188-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target. The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04585035, a Phase 1 study of Solid Tumor, Adult and NSCLC, is active but no longer recruiting, sponsored by InventisBio Co..

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.

Conditions Studied

Solid Tumor, Adult NSCLC CRC

Interventions

  • DRUG D-1553
  • DRUG D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other

Study Locations (20)

New South Wales

  • Research Site - Blacktown
  • Research Site - East Albury
  • Research Site - Kogarah
  • Research Site - Waratah

California

  • Research Site - Fresno
  • Research Site - Orange
  • Research Site - San Francisco

Victoria

  • Research Site - Fitzroy
  • Research Site - Frankston
  • Research Site - Malvern

Other

  • Research Site - Seoul
  • Research Site - Seoul

Kentucky

  • Research Site - Louisville

Michigan

  • Research Site - Detroit

New York

  • Research Site - New York

Oregon

  • Research Site - Portland

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2020-10-02
Est. Completion 2025-12
Phase Phase 1

Sponsor

InventisBio Co.

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04585035

The ClinicalTrials.gov registry entry for NCT04585035 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 188-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target. The listed sponsor is InventisBio Co., which has 11 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Solid Tumor, Adult appearing as the primary indexed condition, and to 2 interventions - of which D-1553 is the first listed.

NCT04585035 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New South Wales, California, Victoria.

Frequently Asked Questions

What is clinical trial NCT04585035 about?

NCT04585035 is a clinical study titled "Study to Evaluate D-1553 in Subjects With Solid Tumors". This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.

What is the current status of trial NCT04585035?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2020-10-02. Estimated completion is 2025-12.

What conditions does trial NCT04585035 study?

This clinical trial studies the following conditions: Solid Tumor, Adult, NSCLC, CRC.

What interventions are being tested in trial NCT04585035?

The interventions under investigation include: D-1553 (DRUG), D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other (DRUG).

Who is sponsoring clinical trial NCT04585035?

This trial is sponsored by InventisBio Co., which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04585035 being conducted?

This trial has 20 study locations across California, Kentucky, Michigan, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor, Adult

All registered trials for this condition

NSCLC

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.